Revvity (NYSE:RVTY) Shares Unloaded Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently sold shares of Revvity, Inc. NYSE: RVTY. In a filing disclosed on March 20th, the Representative disclosed that they had sold between $15,001 and $50,000 in Revvity stock on February 28th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Laboratory Co. of America NYSE: LH on 2/28/2025.
• Purchased $15,001 - $50,000 in shares of Corpay NYSE: CPAY on 2/28/2025.
• Sold $1,001 - $15,000 in shares of Tempur Sealy International NYSE: TPX on 2/28/2025.
• Purchased $1,001 - $15,000 in shares of CACI International NYSE: CACI on 2/27/2025.
• Purchased $1,001 - $15,000 in shares of Laboratory Co. of America NYSE: LH on 2/27/2025.
• Purchased $1,001 - $15,000 in shares of Paychex NASDAQ: PAYX on 2/27/2025.
• Sold $15,001 - $50,000 in shares of Teledyne Technologies NYSE: TDY on 2/22/2025.
• Purchased $1,001 - $15,000 in shares of Corpay NYSE: CPAY on 2/22/2025.
• Sold $1,001 - $15,000 in shares of Tempur Sealy International NYSE: TPX on 2/22/2025.
• Sold $1,001 - $15,000 in shares of CACI International NYSE: CACI on 2/22/2025.

Revvity Trading Down 1.4 %

Shares of Revvity stock traded down $1.53 during trading hours on Tuesday, hitting $107.06. The company's stock had a trading volume of 1,290,812 shares, compared to its average volume of 849,400. Revvity, Inc. has a twelve month low of $97.32 and a twelve month high of $129.50. The stock has a market cap of $12.86 billion, a price-to-earnings ratio of 48.44, a P/E/G ratio of 3.82 and a beta of 1.06. The firm has a fifty day moving average of $116.15 and a 200-day moving average of $117.48. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60.

Remove Ads

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the previous year, the business earned $1.25 EPS. Research analysts forecast that Revvity, Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be given a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.26%. Revvity's dividend payout ratio is currently 12.67%.

Institutional Trading of Revvity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVTY. Nissay Asset Management Corp Japan ADV grew its position in shares of Revvity by 0.6% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 15,023 shares of the company's stock valued at $1,682,000 after buying an additional 91 shares during the last quarter. Quarry LP grew its holdings in shares of Revvity by 45.7% during the fourth quarter. Quarry LP now owns 303 shares of the company's stock worth $34,000 after purchasing an additional 95 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Revvity by 2.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,214 shares of the company's stock worth $470,000 after purchasing an additional 100 shares in the last quarter. HB Wealth Management LLC lifted its holdings in shares of Revvity by 4.6% in the 4th quarter. HB Wealth Management LLC now owns 2,380 shares of the company's stock valued at $266,000 after purchasing an additional 104 shares during the last quarter. Finally, Signaturefd LLC boosted its position in shares of Revvity by 6.8% in the 4th quarter. Signaturefd LLC now owns 1,668 shares of the company's stock valued at $186,000 after purchasing an additional 106 shares during the period. Institutional investors and hedge funds own 86.65% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on RVTY. Raymond James reaffirmed an "outperform" rating and set a $145.00 target price (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Sanford C. Bernstein cut Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective on the stock. in a research note on Friday, January 10th. Bank of America raised Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price for the company in a research note on Friday, December 13th. Barclays increased their price target on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Finally, KeyCorp boosted their price objective on Revvity from $132.00 to $145.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Revvity currently has an average rating of "Moderate Buy" and an average target price of $136.25.

Insider Buying and Selling

In related news, insider Joel S. Goldberg sold 15,170 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the transaction, the insider now owns 33,400 shares of the company's stock, valued at $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Tajinder S. Vohra sold 5,492 shares of Revvity stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by company insiders.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.